Affected by favorable policies, while the prospects of the Chinese medicine market are good, Chinese medicine stocks are also ushering in a sharp rise
.
It is understood that since the beginning of this year, the A-share traditional Chinese medicine sector has risen significantly
.
For example, in recent times, many Chinese medicine stocks have been frequently rising and stopping
.
Today, Guizhou Bailing touched the limit board, closing at 8.
13 yuan
.
The stock rose to a limit at 10:21, opened a limit once, and closed with a capital of 78.
7896 million yuan, accounting for 0.
9%
of its circulating market value.
Industry analysts believe that the main reasons for the change in the stock are: the company is a seedling drug research and development and production enterprise
.
The company's products mainly include cough phlegm medicine, cold medicine, cardiovascular and cerebrovascular medicine and other proprietary Chinese medicines; The company's cold products include vitamin C silver warp tablets, golden sense capsules, wind chill/wind heat cold granules, banlangen granules, pediatric aminophenolamine granules, compound aminophenolamine capsules, etc.
; Yunnan Plant Pharmaceutical Co.
, Ltd.
, a shareholding subsidiary of Guizhou Bailing, has obtained the medical device registration certificate issued by the Yunnan Provincial Food and Drug Administration, marking that Yunzhi Pharmaceutical has officially obtained the production license for medical disposable protective clothing and has become the first enterprise with production qualifications in Yunnan Province
.
It is understood that Guizhou Bailing is a hot stock
of CAR-T therapy, traditional Chinese medicine, and innovative drug concept.
On the evening of October 26, Guizhou Bailing released the third quarter report of 2022, showing that the company's operating income in the first three quarters was 2.
099 billion yuan, a year-on-year increase of 6.
09%.
In the first three quarters, Guizhou Bailing took "seeking progress in stability" as the general keynote, carried out various business work in an orderly manner around the annual business plan, and fully promoted the resumption of work and production, ensuring the continuity and stability of the company's operation, so although the net profit declined, it still achieved stable profits
in the first three quarters.
It is worth mentioning that in the context of favorable industry and the company's own stable profits, the stock has risen 8 times
in the past year.
On March 28, Guizhou Bailing closed at a closing price of 8.
23 yuan
.
As of the closing of the market, the capital of the closed order was 131 million yuan, accounting for 1.
7%
of its circulating market value.
At 9:53 on March 31, Guizhou Bailing closed the price of 10.
96, up 10.
04%.
.
.
Industry analysts believe that the stock may continue to have high momentum in the future
.
Since October, in fact, the Chinese medicine sector has been continuously rising, and at the same time, there are frequent individual stocks up and down
.
For example, on November 22, Jinling Pharmaceutical rose and closed, with a quotation of 9.
22 yuan, a turnover of 359 million, a turnover rate of 7.
94%, a price-to-earnings (TTM) of 40.
55, and a total market value of 4.
706 billion
.
On November 14, China Resources Sanjiu, Huluwa, Jichuan Pharmaceutical closed the board in the afternoon, Sunflower Pharmaceutical, Yiling Pharmaceutical, Tailong Pharmaceutical, Teyi Pharmaceutical, Zhongsheng Pharmaceutical, etc.
previously rose to the limit, Kangyuan Pharmaceutical, Taiji Group, Renhe Pharmaceutical, Jianmin Group, etc.
rose by more than 8%.
On November 18, the traditional Chinese medicine sector rose, Kangyuan Pharmaceutical, Jinling Pharmaceutical, Teyi Pharmaceutical, Tailong Pharmaceutical, etc.
collectively rose to the limit, Jinhua Shares, Biovalley, Fangsheng Pharmaceutical, etc.
followed higher.
.
.
Among them, like Guizhou Bailing, there are many frequent ups and
downs.
It is reported that Teyi Pharmaceutical has increased the limit 11 times in the past year, and Miracle Pharmaceutical has also increased the limit 16 times
in the past year.
Industry analysts believe that the state's vigorous promotion of the inheritance and innovation of the traditional Chinese medicine industry, as well as the significant improvement of the efficiency of the review and approval of traditional Chinese medicine, have injected a "strong shot" into the development of traditional Chinese medicine, and will continue to drive the traditional Chinese medicine sector to rise
again.
For the future market, many securities institutions have expressed optimism about the future market of the traditional Chinese medicine sector
.
Against this backdrop, more stocks are expected to rise to the limit
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
